Can cardiac resynchronization therapy cause harm?
نویسندگان
چکیده
منابع مشابه
Can cardiac resynchronization therapy cause harm?
Most beneficial and effective therapies also have the potential to cause harm. Cardiac resynchronization therapy (CRT) is now proven by large-scale clinical trials to be highly beneficial for chronic heart failure patients, with reduction in mortality and re-hospitalization, and improved quality of life. However, it does have potential adverse effects such as those associated with any pacemaker...
متن کاملCan cardiac resynchronization therapy improve cognitive function? A systematic review.
INTRODUCTION Cognitive impairment (CI) comprises a measurable deficit of different cognitive domains (memory, attention, problem solving, and motor speed), and has a high prevalence among congestive heart failure (CHF) patients. Only a few pilot studies have investigated the effects of cardiac resynchronization therapy (CRT) on cognitive performance. The purpose of this systematic review is to ...
متن کاملCardiac-resynchronization therapy.
Cardiac resynchronization therapy (CRT) addresses abnormal left ventricular (LV) activation that produces detrimental effects on cardiac systolic and diastolic function. CRT improves symptoms and ventricular performance, promotes reverse remodeling, and decreases mortality and hospitalization in patients with congestive heart failure (CHF). Atrial-synchronized biventricular stimulation reverses...
متن کاملCardiac Resynchronization Therapy
According to the 2013 update on heart disease statistics from American Heart Association, an estimated 5.1 million Americans ≥20 years of age have a diagnosis of heart failure. In the year 2009, heart failure was noted to be the primary cause of death in >56 000 people and contributed to death of >274 000 people. It is one of the most common causes of hospitalization in patients ≥65 years of ag...
متن کامل[Cardiac resynchronization therapy].
Fifteen years after the birth of resynchronization therapy, this technique has become one of the recommended treatments in severe heart failure patients, with low ejection fraction (4 35%), and conduction disorders (ORS > or = 120 ms). Based on large randomized clinical trials, the European recommendation is class I type (level of evidence A), to improve symptoms and survival of this patient po...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2012
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehr478